Devgen and PT (Persero) Sang Hyang Seri sign memorandum of understanding on the introduction of biotech rice in Indonesia

Ghent - Jakarta, 17 June 2010. Devgen and PT (Persero) Sang Hyang Seri (SHS) herewith further strengthen their relationship. The companies have already ongoing agreements for R&D, production and distribution of non-transgenic hybrid rice in Indonesia. "Bringing biotech traits to market will take several years and is a complex and stepwise regulatory and research process." Says Dr. Thierry Bogaert. "We are pleased to further strengthen our relationship with SHS, a strong partner in Indonesia." "We are pleased to work with Devgen, a leader in rice trait and hybrid seed technology" says Mr. Eddy Budiono, the President Director of Sang Hyang Seri. "With this cooperation we will, as per government guidance, provide the Indonesian farmer with the best, locally produced, hybrid rice to increase yield and productivity in the country. The result will be significantly realized in the next few years. " Indonesia is South East Asia's largest rice growing country with approximately 12 million ha under rice cultivation. About SHS Pt Sang Hyang Seri is a government wholly owned company dealing with seed, fertilizer and agrochemicals with offices and farms across Indonesia. About Devgen nv Devgen's mission is to enable farmers to sustainably grow more food on less land, with less water, agrochemicals and labour. Devgen uses advanced biotechnology and molecular breeding technology to make high yielding seeds and crop protection solutions with a superior environmental profile. Devgen brings this technology to the market in the world's major food and feed crops through two complementary strategies: -   licensing Devgen technology for use in corn, cotton and soy and selected other crops in exchange for R&D funding, and milestone and royalty payments; -   producing and selling its premium hybrid seeds in major field crops such as rice, sunflower, sorghum, and pearl millet, in the Indian subcontinent and South-East Asia. In its Crop Protection unit, Devgen developed an agro-chemical product that protects crops from damage by parasitic nematodes. This nematicide was launched in Turkey and in US. Incorporated in 1997, Devgen has offices in Ghent (Belgium), and has subsidiaries in Singapore, Hyderabad (India), General Santos (Philippines) and Delaware (US), totalling about 280 employees. For more information please contact: Thierry Bogaert, CEO Wim Goemaere, CFO Tel. +32 9 324 24 24 Tel. +32 9 324 24 24 Or visit: This press release may contain forward-looking statements containing the words "anticipates", "expects" , "intends", "plans", "estimates", "may" and "continues" as well as similar expressions. Such forward looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, performance or achievements of Devgen to be materially different from any future results or achievements expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: agricultural risks and difficulties, including weather factors, diseases and pests, the costs and requirements of regulatory compliance and the speed with which approvals are received; public acceptance of biotechnology products; political, economic and social developments in countries where Devgen operates and other risks and factors detailed in the company's most recent annual report. These forward looking statements speak only as of the date of publication of this document. Devgen disclaims any obligation to update such forward looking statements in this document to reflect any change in its expectations, conditions or circumstances on which such statement is based, unless required by law or regulation. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any securities issued by Devgen NV. [HUG#1424563] PR ENG FINAL: